Investment Analysts’ Weekly Ratings Changes for Illumina (ILMN)

Illumina (NASDAQ: ILMN) recently received a number of ratings updates from brokerages and research firms:

• 6/29/2026 – Illumina had its price target raised by Guggenheim from $180.00 to $200.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Illumina is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $185.00 price target on the stock.
• 6/25/2026 – Illumina was upgraded by Sanford C. Bernstein to “hold”.
• 6/24/2026 – Illumina had its price target raised by Barclays PLC from $122.00 to $145.00. They now have an “underweight” rating on the stock.
• 6/10/2026 – Illumina was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $185.00 price target on the stock, up from $125.00.
• 6/3/2026 – Illumina was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 6/1/2026 – Illumina had its price target raised by Guggenheim from $170.00 to $180.00. They now have a “buy” rating on the stock.
• 5/14/2026 – Illumina is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $170.00 price target on the stock.
• 5/14/2026 – Illumina was upgraded by Royal Bank Of Canada to “moderate buy”.
• 5/14/2026 – Illumina was upgraded by Daiwa Securities Group Inc. from “neutral” to “outperform”. They now have a $155.00 price target on the stock.
• 5/9/2026 – Illumina was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/4/2026 – Illumina had its price target raised by Citigroup Inc. from $80.00 to $95.00. They now have a “sell” rating on the stock.
• 5/1/2026 – Illumina had its “outperform” rating reaffirmed by Evercore Inc.
• 5/1/2026 – Illumina had its price target lowered by Canaccord Genuity Group Inc. from $150.00 to $140.00. They now have a “hold” rating on the stock.
• 5/1/2026 – Illumina had its price target raised by Barclays PLC from $110.00 to $122.00. They now have an “underweight” rating on the stock.
• 5/1/2026 – Illumina had its price target raised by JPMorgan Chase & Co. from $120.00 to $125.00. They now have a “neutral” rating on the stock.

Insiders Place Their Bets

In other news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the transaction, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. This trade represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the transaction, the chief accounting officer directly owned 14,946 shares in the company, valued at approximately $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by corporate insiders.

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.